European Union - English - EMA (European Medicines Agency)

janssen-cilag international n.v.    - amivantamab - carcinoma, non-small-cell lung - antineoplastic agents - rybrevant as monotherapy is indicated for treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (nsclc) with activating epidermal growth factor receptor (egfr) exon 20 insertion mutations, after failure of platinum-based chemotherapy.

Canada - English - Health Canada

pfizer canada ulc - elranatamab - solution - 44mg - elranatamab 44mg

Canada - English - Health Canada

pfizer canada ulc - elranatamab - solution - 76mg - elranatamab 76mg

Singapore - English - HSA (Health Sciences Authority)

roche singapore pte. ltd. - polatuzumab vedotin - injection, powder, lyophilized, for solution - polatuzumab vedotin 140 mg

Canada - English - Health Canada

incyte corporation - tafasitamab - powder for solution - 200mg - tafasitamab 200mg - antineoplastic agents

European Union - English - EMA (European Medicines Agency)

incyte biosciences distribution b.v. - tafasitamab - lymphoma, large b-cell, diffuse - antineoplastic agents - minjuvi is indicated in combination with lenalidomide followed by minjuvi monotherapy for the treatment of adult patients with relapsed or refractory diffuse large b-cell lymphoma (dlbcl) who are not eligible for autologous stem cell transplant (asct).

Singapore - English - HSA (Health Sciences Authority)

roche singapore pte. ltd. - polatuzumab vedotin - injection, powder, lyophilized, for solution - polatuzumab vedotin 30mg/vial

Canada - English - Health Canada

gilead sciences canada inc - sacituzumab govitecan - powder for solution - 180mg - sacituzumab govitecan 180mg - antineoplastic agents

Canada - English - Health Canada

janssen inc - amivantamab - solution - 350mg - amivantamab 350mg

Singapore - English - HSA (Health Sciences Authority)

johnson & johnson international (singapore) pte ltd - amivantamab - infusion, solution concentrate - amivantamab 350mg/7ml